4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

pharmafile | February 22, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease 

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com this week, including Keytruda’s liver cancer failure, a “game-changing osteoasrthritis treatment, AstraZeneca’s retirement of the MedImmune brand, and the promise of the first new asthma pill in two decades.

10. Poland and Slovenia included in US-EU mutual recognition agreement

Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to the United States.

9. Keytruda falls short at Phase 3 in advanced liver cancer

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda, in combination with best supportive care, failed to meet its primary endpoints in advanced liver cancer.

8. Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior to glimepiride in its ability to prolong the amount of time before the first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke in type 2 diabetes patients.

7. Intercept’s NASH liver fibrosis drug shows promise at Phase 3

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH), sending the company’s shares up by 32%.

6. Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a Rheumatology Data Safety Monitoring Board (DSMB) highlighted safety concerns in the higher of the two doses.

5. “Game-changing” osteoarthritis drug receives £675k funding from Innovate UK

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from Innovate UK.

4. China to establish national rare disease network

China is set to establish a national collaborative network of hospitals for rare disease diagnosis and treatment to promote early detection and effective treatment of rare diseases.

3. Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials.

2. AstraZeneca to retire MedImmune brand amid restructuring

AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.

1. First asthma pill in two decades could treat condition by reducing airway muscle

Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an investigational pill for the treatment of asthma. The oral, selective prostaglandin D2 receptor antagonist, known as Fevipiprant, is the first of its kind for two decades.

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug

German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has …

Latest content